ANTI-ORTHOPOXVIRUS DRUG DISCOVERY AND DEVELOPMENT

抗正痘病毒药物的发现和开发

基本信息

  • 批准号:
    6216811
  • 负责人:
  • 金额:
    $ 54.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2000
  • 资助国家:
    美国
  • 起止时间:
    2000-08-15 至 2004-07-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (adapted from applicant's abstract): The possibility of biological terrorism has moved from the realm of speculation into reality. This threat can take several forms. One of the most likely pathogens in such a scenario is smallpox. The same characteristics that made smallpox a dreaded human pathogen, including aerosol infectivity and stability outside a human host, make it a potentially devastating biological weapon. Dissemination of smallpox in a major population center could result in the sudden, simultaneous occurrence of thousands of cases of severe illness. The primary reason for this is that so few people are now protected from infection by prior vaccination as a consequence of the declaration in 1980 of the complete eradication of smallpox. Furthermore, vaccination would be of little benefit to persons already infected by terrorist release of the virus and immediate vaccination of the exposed population might not reduce the infectivity of primary cases to prevent secondary transmission. Vaccine availability and quality would also prevent a massive vaccination effort. Because of these limitations, development of chemotherapeutic agents to combat smallpox infection must be undertaken. No such agents currently exist. To address this need, this proposal presents plans for developing drugs that act by inhibiting the enzymes encoded by the smallpox virus upon infection. Focus will be on nucleosides and nucleotides that effect, primarily, nucleic acid metabolism. A consortium of three chemists and two virologists as project leaders, and a virologist consultant, has been put into place for this purpose.
描述(改编自申请人摘要):生物学的可能性

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Stewart W. Schneller其他文献

2- and 3-Fluoro-3-deaza-1′,6′-isoneplanocin: Synthesis and antiviral properties (including Ebola and Marburg)
  • DOI:
    10.1016/j.bmcl.2023.129219
  • 发表时间:
    2023-04-01
  • 期刊:
  • 影响因子:
  • 作者:
    Chong Liu;Qi Chen;Stewart W. Schneller
  • 通讯作者:
    Stewart W. Schneller
6′-Fluoro-3-deazaneplanocin: Synthesis and antiviral properties, including Ebola
  • DOI:
    10.1016/j.bmcl.2018.10.030
  • 发表时间:
    2018-12-15
  • 期刊:
  • 影响因子:
  • 作者:
    Chong Liu;Qi Chen;Steven Cardinale;Terry L. Bowlin;Stewart W. Schneller
  • 通讯作者:
    Stewart W. Schneller

Stewart W. Schneller的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Stewart W. Schneller', 18)}}的其他基金

Therapeutics for Pox, Filo and Other Viral Pathogens
痘、丝状病毒和其他病毒病原体的治疗
  • 批准号:
    6689700
  • 财政年份:
    2003
  • 资助金额:
    $ 54.75万
  • 项目类别:
Therapeutics for Pox, Filo and Other Viral Pathogens
痘、丝状病毒和其他病毒病原体的治疗
  • 批准号:
    7015066
  • 财政年份:
    2003
  • 资助金额:
    $ 54.75万
  • 项目类别:
Therapeutics for Pox, Filo and Other Viral Pathogens
痘、丝状病毒和其他病毒病原体的治疗
  • 批准号:
    7188078
  • 财政年份:
    2003
  • 资助金额:
    $ 54.75万
  • 项目类别:
Therapeutics for Pox, Filo and Other Viral Pathogens
痘、丝状病毒和其他病毒病原体的治疗
  • 批准号:
    6850768
  • 财政年份:
    2003
  • 资助金额:
    $ 54.75万
  • 项目类别:
Therapeutics for Pox, Filo and Other Viral Pathogens
痘、丝状病毒和其他病毒病原体的治疗
  • 批准号:
    6785825
  • 财政年份:
    2003
  • 资助金额:
    $ 54.75万
  • 项目类别:
Inhibition of Orthopoxvirus AdoHcy/AdoMet Metabolism
正痘病毒 AdoHcy/AdoMet 代谢的抑制
  • 批准号:
    6631225
  • 财政年份:
    2002
  • 资助金额:
    $ 54.75万
  • 项目类别:
Inhibition of Orthopoxvirus AdoHcy/AdoMet Metabolism
正痘病毒 AdoHcy/AdoMet 代谢的抑制
  • 批准号:
    6482449
  • 财政年份:
    2001
  • 资助金额:
    $ 54.75万
  • 项目类别:
ANTI-ORTHOPOXVIRUS DRUG DISCOVERY AND DEVELOPMENT
抗正痘病毒药物的发现和开发
  • 批准号:
    6374676
  • 财政年份:
    2000
  • 资助金额:
    $ 54.75万
  • 项目类别:
Inhibition of Orthopoxvirus AdoHcy/AdoMet Metabolism
正痘病毒 AdoHcy/AdoMet 代谢的抑制
  • 批准号:
    6347073
  • 财政年份:
    2000
  • 资助金额:
    $ 54.75万
  • 项目类别:
ANTI-ORTHOPOXVIRUS DRUG DISCOVERY AND DEVELOPMENT
抗正痘病毒药物的发现和开发
  • 批准号:
    6532843
  • 财政年份:
    2000
  • 资助金额:
    $ 54.75万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 54.75万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 54.75万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 54.75万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 54.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 54.75万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 54.75万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 54.75万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 54.75万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 54.75万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 54.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了